These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14621603)

  • 1. [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
    Maev IV; Kucheriavyĭ IuA; Danilin MS
    Eksp Klin Gastroenterol; 2003; (5):10-2, 192. PubMed ID: 14621603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Some comparative aspects of treating the gastroesophageal reflux disease eradication].
    Minushkin ON; Maslovskiĭ LV; Anikina NIu
    Eksp Klin Gastroenterol; 2004; (3):45-8, 104. PubMed ID: 15560401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
    Minushkin ON; Maslovskiĭ LV; Anikina NIu; Shuleshova AG
    Eksp Klin Gastroenterol; 2005; (2):29-35. PubMed ID: 15932152
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharma-clinics medication of the month. Rabeprazole (Pariet)].
    Louis E
    Rev Med Liege; 2002 Jan; 57(1):53-6. PubMed ID: 11899500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
    Miner P; Orr W; Filippone J; Jokubaitis L; Sloan S
    Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A; Wruble LD; Humphries TJ
    Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy.
    Katzka DA; Paoletti V; Leite L; Castell DO
    Am J Gastroenterol; 1996 Oct; 91(10):2110-3. PubMed ID: 8855731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].
    Vasil'ev IuV; Noskova KK; Zelenikin SA
    Eksp Klin Gastroenterol; 2002; (1):55-60, 190. PubMed ID: 12271586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
    Khavkin AI; Zhikhareva NS; Rachkova NS; Babaian ML; Volynets GV; Khanakaeva ZK
    Eksp Klin Gastroenterol; 2004; (2):53-6. PubMed ID: 15462323
    [No Abstract]   [Full Text] [Related]  

  • 11. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral cavity manifestations of gastroesophageal reflux disease].
    Maev IV; Barer GM; Busarova GA; Pustovoĭt EV; Polikanova EN; Burkov SG; Gurenev GL
    Klin Med (Mosk); 2005; 83(11):33-8. PubMed ID: 16404937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical aspects of using pariet in treating chronic pancreatitis].
    Sablin OA; Ratnikov VA; Butenko EV; Pakhomova IG
    Eksp Klin Gastroenterol; 2002; (5):73-6, 129. PubMed ID: 12619583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
    Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
    Maev IV; Balashova NN; Busarova GA
    Klin Med (Mosk); 2003; 81(9):54-9. PubMed ID: 14598594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
    Törüner M; Bektaş M; Cetinkaya H; Soykan I; Ozden A
    Turk J Gastroenterol; 2004 Dec; 15(4):225-8. PubMed ID: 16249975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of rabeprazole in gastroesophageal reflux disease: report of a multicenter study.
    Kar P; Chandrashekar N; Devi S; Bhatia SJ; Alvares JF; Taneja A; Towar A
    Indian J Gastroenterol; 2003; 22(4):153. PubMed ID: 12962446
    [No Abstract]   [Full Text] [Related]  

  • 19. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():30-7. PubMed ID: 15496216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative clinical and economic efficiency of new generation proton pump inhibitors in the treatment of gastroesophageal reflux].
    Starostin BD; Starostina GA
    Eksp Klin Gastroenterol; 2003; (5):35-9. PubMed ID: 14621608
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.